Modality
ADC
MOA
FGFRi
Target
MDM2
Pathway
mTOR
Melanoma
Development Pipeline
Preclinical
~Apr 2017
→ ~Jul 2018
Phase 1
~Oct 2018
→ ~Jan 2020
Phase 2
~Apr 2020
→ ~Jul 2021
Phase 3
Oct 2021
→ May 2025
Phase 3Current
NCT04465756
1,984 pts·Melanoma
2023-09→2025-05·Recruiting
NCT05893354
769 pts·Melanoma
2021-10→TBD·Active
2,753 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-05-2210mo agoPh3 Readout· Melanoma
Trial Timeline
Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2
P3
Active
P3
Recruit…
Catalysts
Ph3 Readout
2025-05-22 · 10mo ago
Melanoma
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04465756 | Phase 3 | Melanoma | Recruiting | 1984 | OS |
| NCT05893354 | Phase 3 | Melanoma | Active | 769 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1956 | Eli Lilly | Phase 1/2 | BCMA | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| SRP-9822 | Sarepta | Phase 3 | SOS1 | |
| SRP-1135 | Sarepta | Phase 2/3 | MDM2 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 |